Naomi Wolf: Pfizer, Myfembree, and women’s reproductive health - Steve Bannon

Naomi Wolf, a vocal advocate for women’s health, has highlighted research by Dr. James Thorpe, a board-certified obstetrician-gynecologist, that raises troubling questions about Pfizer’s mRNA COVID-19 vaccine and its potential effects on women’s fertility.

In a recent discussion, Wolf referenced Thorpe’s findings, which she claims point to a disturbing connection between the vaccine, a drug called Myfembree, and widespread reproductive health issues. In May 2021, Pfizer partnered with Myovant Sciences to develop Myfembree, an FDA-approved pill for managing heavy menstrual bleeding due to uterine fibroids and later endometriosis pain.

At the same time, Wolf cites analysis of Pfizer’s internal documents, obtained through the War Room/DailyClout Pfizer Documents Research Volunteers, which reportedly show significant menstrual disruptions in women post-vaccination.

2022 study, published in the Journal of the American Physicians and Surgeons, analyzed data from the CDC’s Vaccine Adverse Events Reporting System (VAERS) from 1998 to 2022. It found that, compared to influenza vaccines, COVID-19 vaccines were associated with significantly higher rates of adverse events, including menstrual abnormalities, miscarriages, and fetal deaths (all proportional reporting ratios > 2.0, p-values < 0.05).

Wolf alleges that Pfizer’s data, submitted to the FDA and White House on April 20, 2021, documented tens of thousands of women experiencing issues post-vaccination: 15,000 with daily bleeding, 10,000 with twice-monthly bleeding, 7,500 with absent periods (potentially indicating infertility), and abnormal bleeding in 10-year-old girls and 85-year-old women, alongside reports of hemorrhages and miscarriages. Three days later, Dr. Rochelle Walensky stated the vaccine was safe for women before, during, or after pregnancy.

Wolf finds it concerning that Pfizer was developing Myfembree, which reduces heavy menstrual bleeding by 82-84%, during this period. She questions whether the drug was intended to address bleeding issues allegedly linked to the vaccine. Myfembree’s side effects include reduced estrogen, increased risk of pregnancy loss, blood clots, hair loss, reduced libido, depression, and suicidal thoughts.

Wolf warns that women experiencing vaccine-related bleeding may be prescribed Myfembree, potentially worsening fertility and health. Wolf also references a report from the Czech Republic indicating a 30% drop in live births, steeper than the previously noted 13-20% decline, and questions whether this aligns with Thorpe’s findings of fertility impacts. She emphasizes that no evidence proves deliberate intent, but the timeline and data warrant investigation through public hearings.

Additionally, Wolf notes Myfembree’s ingredients are linked to contraception and assisted reproduction, raising concerns about its broader reproductive impact. She connects this to challenges in domestic drug manufacturing, addressed by President Trump’s executive order to prioritize U.S. production. Wolf urges transparency: “This is a critical issue for women’s health. We need open dialogue and accountability.”